| Adjuvant |
| Cisplatin + Vinorelbine (NCIC BR.10) |
|
| Locally advanced |
| CALGB 84-33 |
|
| RTOG 9410 |
|
| Carbo AUC 2 + paclitaxel 45 qsem + RT (LAMP) |
|
| Durvalumab post chemoradiotherapy |
|
| Metastatic |
| Pembrolizumab |
|
| Pembrolizumab + platinum-based drug + pemetrexed |
|
| Pembrolizumab + paclitaxel + carboplatin |
|
| Carboplatin + pemetrexed |
|
| Cisplatin + Pemetrexed |
|
| Carboplatin + Gemcitabine |
|
| Cisplatin + Gemcitabine |
|
| Carboplatin + Paclitaxel (SWOG 9509) |
|
| Cisplatin + vinorelbine (SWOG 9308) |
|
| Nivolumab |
|
| Atezolizumab |
|
| Docetaxel q 3 wk |
|
| Pemetrexed |
|
| Vinorelbine |
|
| Erlotinib |
|
| mutated ALK |
| Alectinib |
|
| Crizotinib |
|
| Lorlatinib |
|
| Ceritinib |
|
| Brigatinib |
|
| mutated EGFR |
| Osimertinib |
|
| Gefitinib |
|
| Afatinib |
|
| Dacomitinib |
|
| BRAF mutation |
| Dabrafenib + trametinib |
|
| mutated ROS |
| Crizotinib |
|
| mutated KRAS p.G12C |
| mutated MET |
| Maintenance |
| Pemetrexed |
|
Groupe d'étude en oncologie du Québec